相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Lenalidomide and Chronic Lymphocytic Leukemia
Ana Pilar Gonzalez-Rodriguez et al.
BIOMED RESEARCH INTERNATIONAL (2013)
Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response
Asher A. Chanan-Khan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Tumor Flare Reaction Associated With Lenalidomide Treatment in Patients With Chronic Lymphocytic Leukemia Predicts Clinical Response
Asher Chanan-Khan et al.
CANCER (2011)
Treatment With Lenalidomide Modulates T-Cell Immunophenotype and Cytokine Production in Patients With Chronic Lymphocytic Leukemia
Bang-Ning Lee et al.
CANCER (2011)
Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia
Farrukh T. Awan et al.
LEUKEMIA & LYMPHOMA (2010)
Prognostic significance of CD8 and CD4 T cells in chronic lymphocytic leukemia
Ana P. Gonzalez-Rodriguez et al.
LEUKEMIA & LYMPHOMA (2010)
Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics
Taimur Sher et al.
LEUKEMIA & LYMPHOMA (2010)
Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia
Georg Aue et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Mechanism of action of lenalidomide in hematological malignancies
Venumadhav Kotla et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2009)
HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer
A. Lopez-Soto et al.
ONCOGENE (2009)
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia
Alessandra Ferrajoli et al.
BLOOD (2008)
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia:: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
Michael Hallek et al.
BLOOD (2008)
The immunodeficiency of chronic lymphocytic leukaemia
A. D. Hamblin et al.
BRITISH MEDICAL BULLETIN (2008)
Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
Lei Wu et al.
CLINICAL CANCER RESEARCH (2008)
Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q-syndrome patients
Andrea Pellagatti et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Multiple myeloma: A prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment
Constantine S. Mitsiades et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2007)
Immune surveillance of tumors
Jeremy B. Swann et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study
Asher Chanan-Khan et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
Paul G. Richardson et al.
BLOOD (2006)
Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications
David H. Chang et al.
BLOOD (2006)
Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model
FJ Hernandez-Ilizaliturri et al.
CLINICAL CANCER RESEARCH (2005)
Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20m Ab) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention
AR Jazirehi et al.
ONCOGENE (2005)
Efficacy of lenalidomide in myelodysplastic syndromes
A List et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application
T Hayashi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Vδ1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid
A Poggi et al.
CANCER RESEARCH (2004)
分享论文
